The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes
Open accessAbstract
Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected populations and whose sufferers have all endured the stigma of a psychosomatic label, as well as the failure of endless pharmacotherapeutic interventions with substandard benefit. The commonality in symptomatology in these conditions displaying hyperalgesia and central sensitization with possible common underlying pathophysiology suggests that a clinical endocannabinoid deficiency might characterize their origin. Its base hypothesis is that all humans have an underlying endocannabinoid tone that is a reflection of levels of the endocannabinoids, anandamide (arachidonylethanolamide), and 2-arachidonoylglycerol, their production, metabolism, and the relative abundance and state of cannabinoid receptors. Its theory is that in certain conditions, whether congenital or acquired, endocannabinoid tone becomes deficient and productive of pathophysiological syndromes. When first proposed in 2001 and subsequently, this theory was based on genetic overlap and comorbidity, patterns of symptomatology that could be mediated by the endocannabinoid system (ECS), and the fact that exogenous cannabinoid treatment frequently provided symptomatic benefit. However, objective proof and formal clinical trial data were lacking. Currently, however, statistically significant differences in cerebrospinal fluid anandamide levels have been documented in migraineurs, and advanced imaging studies have demonstrated ECS hypofunction in post-traumatic stress disorder. Additional studies have provided a firmer foundation for the theory, while clinical data have also produced evidence for decreased pain, improved sleep, and other benefits to cannabinoid treatment and adjunctive lifestyle approaches affecting the ECS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The endogenous cannabinoid system controls extinction of aversive memories
Marsicano, G., Wotjak, C. T., Azad, S. C., Bisogno, T., Rammes, G., Cascio, M. G., Hermann, H., Tang, J., Hofmann, C., Zieglgänsberger, W., et al. (2002) · Nature · doi:10.1038/nature00839 · Cited by 1,728
Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Self-citationCannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793
An endocannabinoid mechanism for stress-induced analgesia
Hohmann, A. G., Suplita, R. L., Bolton, N. M., Neely, M. H., Fegley, D., Mangieri, R., Krey, J. F., Michael Walker, J., Holmes, P. V., Crystal, J. D., et al. (2005) · Nature · doi:10.1038/nature03658 · Cited by 778
Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models
Kreitzer, A. C., & Malenka, R. C. (2007) · Nature · doi:10.1038/nature05506 · Cited by 735
Akbar, A., Yiangou, Y., Facer, P., Walters, J. R. F., Anand, P., & Ghosh, S. (2008) · Gut · doi:10.1136/gut.2007.138982 · Cited by 526
Nurmikko, T. J., Serpell, M. G., Hoggart, B., Toomey, P. J., Morlion, B. J., & Haines, D. (2007) · Pain · doi:10.1016/j.pain.2007.08.028 · Cited by 431 · cited 1×
“0420).(70) While this degree of benefit is yet to be shown in for-”
BackgroundPortenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.01.003 · Cited by 420
Nabilone for the treatment of pain in fibromyalgia.
Skrabek, R. Q., Galimova, L., Ethans, K., & Perry, D. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2007.09.002 · Cited by 384 · cited 1×
“Another group examined nabilone, a semisynthetic THC analog and CB1 agonist of 10-fold higher potency.(65) Forty fibromyalgia patients received nabilone 1 mg BID for 4 weeks.”
BackgroundBerman, J. S., Symonds, C., & Birch, R. (2004) · Pain · doi:10.1016/j.pain.2004.09.013 · Cited by 362
Neumeister, A., Normandin, M. D., Pietrzak, R. H., Piomelli, D., Zheng, M. Q., Gujarro-Anton, A., Potenza, M. N., Bailey, C. R., Lin, S. F., Najafzadeh, S., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.61 · Cited by 361
The Effects of Nabilone on Sleep in Fibromyalgia: Results of a Randomized Controlled Trial
Ware, M. A., Fitzcharles, M.-A., Joseph, L., & Shir, Y. (2010) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e3181c76f70 · Cited by 324
Notcutt, W., Price, M., Miller, R., Newport, S., Phillips, C., Simmons, S., & Sansom, C. (2004) · Anaesthesia · doi:10.1111/j.1365-2044.2004.03674.x · Cited by 305
Autism-Associated Neuroligin-3 Mutations Commonly Disrupt Tonic Endocannabinoid Signaling
Földy, C., Malenka, R. C., & Südhof, T. C. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.036 · Cited by 287
Hill, M. N., Bierer, L. M., Makotkine, I., Golier, J. A., Galea, S., McEwen, B. S., Hillard, C. J., & Yehuda, R. (2013) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2013.08.004 · Cited by 256
Motion Sickness, Stress and the Endocannabinoid System
Choukèr, A., Kaufmann, I., Kreth, S., Hauer, D., Feuerecker, M., Thieme, D., Vogeser, M., Thiel, M., & Schelling, G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010752 · Cited by 140
Cannabis Treatments in Obstetrics and Gynecology: A Historical Review
Russo, E. (2002) · Journal of Cannabis Therapeutics · doi:10.1300/j175v02n03_02 · Cited by 71
Self-citation
Cited by
Rupasinghe, H. P. V., Davis, A., Kumar, S. K., Murray, B., & Zheljazkov, V. D. (2020) · Molecules · doi:10.3390/molecules25184078 · Cited by 260
Marijuana Use in Pregnancy and While Breastfeeding
Metz, T. D., & Borgelt, L. M. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002878 · Cited by 185
Nociplastic pain: the prominent role of non-neuronal cells in central and peripheral sensitization
Lai, W., Tang, X., Chen, S., Zhou, Y., Qi, Z., Cao, M., Yuan, C., Yu, J., & Wen, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1677310 · Cited by 5
Metadata
- Authors
- Russo, E. B.
- Venue
- Cannabis and Cannabinoid Research
- Publisher
- SAGE Publications
- Published
- 2016-12
- Volume
- 1
- Issue
- 1
- Pages
- 154-165
- ISSN
- 2378-8763 (ISSN-L)
- OpenAlex
- W2515727339
- Cited by
- 190
- References
- 18
- FWCI
- 8.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.